AI-Accelerated Discovery
Our proprietary discovery engine couples high-fidelity functional genomics with data-driven mechanistic AI to decode complex cellular signaling networks. By treating biological data as a causal map rather than correlative patterns, we systematically bypass the adaptive resistance, redundancy, and functional compensation that cause single-target monotherapies to fail.
Our Discovery Engine
A four-step pipeline that distills the mathematically impossible combinatorial explosion of drug screening into actionable, highly synergistic therapeutic targets.
Phase 1A
We design optimal, dual-gene gRNA screening panels by mapping large-scale genetic knockdown data onto 3D Protein-Protein Interaction (PPI) networks. This intelligent upfront design maximizes biological mechanism coverage and initiates the extreme data compression required to navigate the combinatorial screening space.
Intelligent Panel Design
Using catalytically inactive Cas9 fused to repressor domains (dCas9-KRAB), our proprietary dual-gene CRISPR knockout screens simultaneously suppress pairs of target loci. This generates clean, low-noise functional phenotypic dropout data, distilling millions of combinatorial possibilities into approximately 15,000 high-signal gene pairs without the genomic instability of double-stranded DNA breaks.
Phase 1B
Combinatorial CRISPRi Screening
Phase 2A
Digital Cellular Twins
We ingest these high-dimensional functional genomics readouts into our disease-specific Large Language Models (LLMs) via a computationally frugal, parameter-efficient supervised fine-tuning pipeline. Our mechanistic AI acts as a puzzle solver, treating every CRISPR result as a clue to build causal, predictive in silicomodels of adaptive cellular signaling and feedback loops.
Phase 2B
Virtual Synergy Profiling
We evaluate a 20,000 × 20,000 small-molecule and biologic drug matrix in silico using our digital cellular twin platform. The trained model decodes the crosstalk between cellular nodes across 400 million potential combinations, applying rigorous statistical filtering to output trustworthy, highly synergistic therapeutic regimens.
Pipeline & Therapeutic Areas
We are advancing our lead oncology program focused on overcoming therapy resistance in advanced prostate tumors through mechanistically guided drug combinations.
Oncology
Lead program targeting mechanistically guided drug combinations to overcome therapy resistance in advanced prostate tumors.
Regenerative Medicine
A parallel program mapping complex neural crest cell development networks to accelerate tissue regeneration.